TriReme Medical (TMI), a Pleasanton, CA-based device company working on a new stent technology, has completed a $15.6 million Series C round. The financing — led by Three Arch Partners and completed by Adams Street Partners — will be used to continue development and ongoing clinical trials of the company’s single-balloon bifurcation stent system.
Privately held TMI believes its stent system may be useful in more than 25% of the 2.2 million angioplasty procedures performed annually worldwide. It is designed to provide the interventional cardiologist with the ease of use, high deliverability and low profile of a main-vessel stent in a device that is designed to effectively scaffold the ostium, or the junction of main and side branches in a coronary vessel.
The system has a lower profile than standard bifurcation stent systems and even some of the leading “workhorse” drug eluting stents used for routine, non-bifurcated lesions. According to TriReme, it is the only stent-delivery system that allows the physician to actively determine the orientation of the stent prior to deployment, to ensure precise positioning.
“The TMI solution is elegant, flexible and as easy to use as any stent on the market today,” said William Harrington, MD, of Three Arch Partners. “We have been very impressed by the progress of the company to date, particularly the clinical results and the simplified procedure that was developed for the treatment of those complex lesions.”